Although this is the case in some RAS mutant tumor types, including some of the NSCLC tested here, our work indicates that some KRAS mutant cancers retain sensitivity to upstream stimuli emanating from extracellular signaling in particular via the HER pathway. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.